ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.04B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.45M
Average 1.66M
Balance Sheet
Inspect the capital base behind the business.
Assets
$1.56B
FY 2025 · Annual
+31.7% YoYLiabilities
$336.81M
FY 2025 · Annual
-26.0% YoYEquity
$1.23B
FY 2025 · Annual
+67.5% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 147.44M | 114.85M | 188.66M | 319.59M | 177.7M |
| Short-term Investments | 373.27M | 301.98M | 250.21M | 436.4M | 641.99M |
| Net Receivables | 65.34M | 63.08M | 102.35M | 104.7M | 148.23M |
| Inventory | 7.88M | 6.64M | 35.82M | 21.95M | 34.67M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 617.82M | 507.94M | 616.13M | 938.32M | 1.06B |
| Property, Plant & Equipment (Net) | 66.32M | 61.59M | 56.47M | 50.79M | 54.87M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 65.49M | 119.78M | 108.89M |
| Long-term Investments | 3.6M | 12.97M | 5.77M | 8.77M | 7.85M |
| Tax Assets | 0 | 0 | 0 | 0 | 249.88M |
| Other Non-current Assets | 12.38M | 5.31M | 5.1M | 70.1M | 80.6M |
| Total Non-current Assets | 82.3M | 79.88M | 132.83M | 249.44M | 502.08M |
| Total Assets | 700.12M | 587.81M | 748.96M | 1.19B | 1.56B |
| Account Payables | 6.88M | 12.75M | 17.54M | 16.19M | 10.9M |
| Short-term Debt | 0 | 0 | 9.41M | 0 | 11.63M |
| Tax Payables | 0 | 377K | 1.56M | 12.02M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.9M | 49.51M | 92.31M | 36.55M | 67.83M |
| Total Current Liabilities | 96.07M | 125.63M | 254.25M | 394.87M | 277.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.03M | 9.07M | 15.15M | 18.06M | 19.14M |
| Total Non-current Liabilities | 63.16M | 61.77M | 62.95M | 60.09M | 59.69M |
| Total Liabilities | 159.23M | 187.4M | 317.2M | 454.96M | 336.81M |
| Common Stock | 16K | 16K | 16K | 16K | 16K |
| Retained Earnings | (2.15B) | (2.37B) | (2.43B) | (2.2B) | (1.81B) |
| Accumulated OCI | (192K) | (975K) | 24K | 292K | 1.45M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 540.89M | 400.41M | 431.76M | 732.79M | 1.23B |
| Total Debt | 64.43M | 62M | 57.21M | 52M | 52.19M |
| Net Debt | (83.01M) | (52.85M) | (131.45M) | (267.59M) | (125.51M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $976.4M |
| Receivables | $161.0M |
| Inventory | $40.4M |
| Other Current | $90.6M |
| Total Current Assets | $1.3B |
| PP&E (Net) | $85.9M |
| Intangible Assets | $135.5M |
| Tax Assets | $226.7M |
| Other Non-current | $77.7M |
| Total Non-current Assets | $525.7M |
| Total Assets | $1.8B |
Analysis
Selected assets total $1.8B for Latest. The largest visible component is Cash & Equivalents at $976.4M, about 54.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Market cap
$9.17B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Market cap
$7.45B
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Market cap
$1.39B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Market cap
$1.25B
Alto Neuroscience, Inc.
NYSE:ANRO
Market cap
$1.18B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Market cap
$348.58M
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Market cap
$308.98M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Market cap
$241.27M
Anavex Life Sciences Corp.
NASDAQ:AVXL
Market cap
$86.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Market cap
$80.59M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 8-K | Current report | Oct 23, 2026 |
How much cash does ACAD have?
ACADIA Pharmaceuticals Inc. (ACAD) reported $177.69M in cash and equivalents in fiscal 2025.
How much debt does ACAD carry?
ACADIA Pharmaceuticals Inc. (ACAD) reported $52.19M of total debt, with net debt of -$125.51M.
Continue the stock analysis
Jump to another research area for this company.